[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100518171":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":25,"centralContacts":31,"locations":25,"responsibleParty":37,"collaborators":39,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":45,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":25,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":67,"whyStopped":25,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":25},{"fullName":5,"class":6},"Medical University of Silesia","OTHER",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"omalizumab","ACTIVE_COMPARATOR","standard antiasthmatic therapy and omalizumab",[13],"Biological: omalizumab",{"label":15,"type":10,"description":16,"interventionNames":17},"oral tablet HDM-immunotherapy","standard antiasthmatic therapy and oral immunotherapy",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"combi therapy","standard antiasthmatic therapy and omalizumab, and oral immunotherapy",[13],{"label":23,"type":24,"description":25,"interventionNames":25},"control","NO_INTERVENTION",null,[27],{"type":28,"name":9,"description":29,"armGroupLabels":30,"otherNames":25},"BIOLOGICAL","adding omalizumab to anti asthmatic therapy",[19,9,15],[32],{"name":33,"role":34,"phone":35,"phoneExt":25,"email":36},"Andrzej Bozek, prof","CONTACT","0048608318547","andrzejbozek@o2.pl",{"type":38,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[40],{"name":41,"class":42},"Centrum Medyczne Andrzej Bożek","UNKNOWN","100518171","phase-4-biologics-and-sublingual-immunotherapy-100518171",false,"NCT06027073","Biologics and Sublingual Immunotherapy","Adding Biological Therapy to Asthmatic Patients on Allergen Immunotherapy to House Dust Mites","BSIPL","Inclusion Criteria:• \\>18 years old\n\n* A total IgE between 30-700 IU\u002FmL\n* Moderate asthma with perennial symptoms confirmed as HDM-driven asthma based on medical history and positive nasal provocation tests, partially controlled asthma;\n* FEV1 \\>70% at baseline;\n* Positive skin prick test results for D. pteronyssinus, D. farinae\n\nExclusion Criteria:\n\n* Sensitisation to other allergens with clinical signs not related to HDM\n* Uncontrolled asthma,\n* Other serious diseases or chronic unstable diseases\n* Allergen immunotherapy during the past 5 years\n* Contraindicating allergen immunotherapy and omalizumab treatment.","ALL","18 Years","65 Years",{"count":55,"type":56},150,"ESTIMATED","INTERVENTIONAL",[59],"PHASE4","Most current studies involve using a biological drug to increase the safety of allergen immunotherapy (AIT) especially in the treatment of food allergies, to avoid the risk of anaphylaxis. However, adding Xolair® to AIT may improve the therapy's effectiveness. There are still few observations on this topic, especially in patients with house dust mite (HDM)-driven asthma.",[62],"Asthma, Allergic",[64,65,9,66],"IgE","asthma","immunotherapy","NOT_YET_RECRUITING","2023-08-30",{"date":70,"type":71},"2023-09-07","ACTUAL",{"date":73,"type":56},"2024-05-01",{"date":75,"type":56},"2028-03-01",{"name":5,"class":6}]